

Charts to the statement at the Annual Shareholders' Meeting in Essen (Germany) on June 2, 2021, 10 a.m.

Christian Kullmann, Chairman of the Executive Board of Evonik Industries AG

Evonik stayed on course in 2020

We delivered ...



... what we promised.

We proved ...



... the quality of our portfolio.

We evolved ...



... and drove our strategy forward.

Proactive against Corona

190,000

nose and mouth masks
distributed worldwide




16,000

employees **working from home** worldwide



220,000

self-test kits provided




8

in-house vaccination centers in Germany
ready to start operation



We delivered what we promised



We proved the quality of our portfolio

Specialty Additives



3,225

857

26.6

Sales
(in € million)

Adj. EBITDA
(in € million)/
margin (in %)

Nutrition & Care



2,992

560

18.7

Sales
(in € million)

Adj. EBITDA
(in € million)/
margin (in %)

Smart Materials



3,234

529

16.4

Sales
(in € million)

Adj. EBITDA
(in € million)/
margin (in %)

Robust Growth Divisions

adj. EBITDA (% yoy) & margin (bp yoy)

-3%

-11%

-10bp

-80bp


Growth Divisions

Evonik
Group

We drove our strategy forward


Sustainability

Portfolio analysis
and definition
of focus areas



Innovation

New structure
successfully
implemented



Acquisitions

Strengthening
of our resilient
businesses

 **PeroxyChem**
An Evonik Company.

POROCCEL
Technology Driven. Value Focused.

Carve-out Baby Care

Focus on specialty
businesses with high
margins and returns



We drove our strategy forward ... and there is more to come

Investments

New production complex
for Polyamid 12



Efficiency

Asset optimization
at Animal Nutrition




Cost discipline

Completion of
SG&A program




Stable dividend and high dividend yield of over 4 percent



- Dividend policy based on **reliability and continuity**
- **Dividend yield of 4.3 percent** among top in the chemical industry

Outlook 2021 – adjusted EBITDA between € 2.1 and € 2.3 billion



1st quarter 2021 – all growth divisions above previous year

Business development very positive in first quarter



All growth divisions above previous year and above the first quarter in 2019



Sales:
€ 3,358 million



Adjusted EBITDA:
€ 588 million



Adjusted earnings per share:
€ 0.51




Evonik shares – share price development 2020 and 2021

Share price development 2020

Evonik: -2%

DJ Stoxx Chemicals 600: +8%

MDAX: +7%




Share price development 2021¹

Evonik: +9%

DJ Stoxx Chemicals 600: +11%

MDAX: +6%



¹ Share price developments YTD until May 25, 2021



EVONIK

Leading Beyond Chemistry